Accession Number:

ADA262447

Title:

Hepatic Metabolism of Perfluorinated Carboxylic Acids and Polycholorotrifluoroethylene: A Nuclear Magnetic Resonance Investigation in Vivo

Descriptive Note:

Annual technical rept. 15 Dec 91-14 Dec 92

Corporate Author:

WRIGHT STATE UNIV DAYTON OH SCHOOL OF MEDICINE

Personal Author(s):

Report Date:

1993-01-14

Pagination or Media Count:

24.0

Abstract:

This report describes our studies of the effects of perfluorooctanoic acid PFOA and perfluorodecanoic acid PFDA on hepatic carbohydrate and phospholipid metabolism. Previously we have shown that PFDA inhibits hepatic glycogenesis from glucose in rats. In recent studies using carbon-13 nuclear magnetic resonance NMR spectroscopy, PFDA-treated rats show active gluconeogenesis from 3-13 Calanine and the incorporation of the 13C label into hepatic glycogen. The rate of alanine utilization is 40 greater in controls than PFDA-treated rats, and liver glucose-6-phosphate levels are about 40 lower in PFDA rats as compared to controls p or 0.02. These results suggest that the PFDA-induced inhibition in glycogenesis from glucose is due to a dysfunction in the glucose transporter andor glucoinase activity. In separate studies involving liver phosphorus metabolism, 31 P NMR was used to examine the effects of PFDA, PFOA, and clofibrate CLOF in both rats and guinea pigs. A unique effect is revealed in PFDA-treated rats in which a significant increase is observed in liver phosphocholine from 2.31 - 0.23 umolg tissue on day 1 post dose to 4.56 - 0.21 umolg on day 5. These level are 2 to 4-fold greater than those measured in controls. The results indicate an enhanced turnover of liver phosphatidylcholine. Ongoing research efforts focus on the effects of PFDA on diacylglycerol levels, phospholipase C activity, and will examine the physical interaction of PFDA with phospholipid membranes.

Subject Categories:

  • Biochemistry

Distribution Statement:

APPROVED FOR PUBLIC RELEASE